IU, Purdue selected for major NCI biomarker tools initiative

INDIANAPOLIS -- The National Institutes of Health's National Cancer Institute has selected a team of scientists from Indiana and Purdue universities to assess and develop the next generation of tools to improve biomarker discovery. Such biomarkers should lead to better prevention, diagnosis and treatment of cancer.

The IU and Purdue Analytical Proteomics Team was awarded a grant of about $7 million as one of five national centers selected by the NCI for its clinical proteomic technologies initiative for cancer, a five-year, $104 million national program. The five grants, totaling $35.5 million, will establish a collaborative network to assess the proteomics technologies used to improve cancer research and treatment.

Proteomics is the study of proteins: their structure, function and how they interact with each other. The goal of the NCI initiative is to enable cancer researchers to make use of standardized proteomics methodologies to discover proteins and protein components -- biomarkers -- that are relevant to cancer.

Indiana is well known for having experts in proteomics at Purdue, IU-Bloomington and the IU School of Medicine in Indianapolis, as well as private industry. The Analytical Proteomics Team grant will pair those proteomics experts with cancer researchers and clinicians at the IU School of Medicine and experts in statistical and computer analysis at IU's School of Informatics.

Fred Regnier, Ph.D., Purdue's John H. Law Distinguished Professor of Chemistry, will be principal investigator for the team.

"This is a perfect example of how great things will happen in Indiana when IU, Purdue and the private sector collaborate on life sciences research," said D. Craig Brater, M.D., vice president of IU with responsibility for life sciences and dean of the IU School of Medicine.

Four hundred clinical samples will be collected for breast cancer analysis by the Hoosier Oncology Group, an Indiana statewide network of cancer physicia

Contact: Eric Schoch
Indiana University

Page: 1 2 3

Related biology news :

1. Purdue-IU researchers explore new method for early disease diagnosis
2. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
3. NIH selects Purdue to use phi29 DNA packaging motor for National Nanomedicine Development Center
4. Purdue creates new low-cost system to detect bacteria
5. Industry, C-SPAN leaders energize Lugar-Purdue summit
6. Purdue researchers find switch for skeletal-muscle atrophy
7. Purdue project could help pets serve as disease watchdogs
8. Purdue biologists clarify how a cellular spacecraft opens its airlock
9. Purdue scientists see biochemistrys future - with quantum physics
10. Purdue scientists treat cancer with RNA nanotechnology
11. Purdue researchers find key to rice blast fungus

Post Your Comments:

(Date:6/13/2020)... ... June 11, 2020 , ... ... a significant expansion of its forensic genealogy team. Bode’s Forensic Genealogy Service ... proven forensic genealogy and DNA analysis methods. The team has added experienced genealogists, ...
(Date:6/5/2020)... ... 04, 2020 , ... “Although we are disappointed to have to make this ... and the public. We remain committed to creating a global platform to showcase ... Julie Sutcliffe, President of WMIS. , The abstract deadline for the ...
(Date:5/28/2020)... ... , ... CrucialTrak, a global designer and manufacturer of biometric access control systems, ... market and sell its complete line of biometric readers and access gates . ... solutions . , Brett Mason, CrucialTrak’s Director of Channel Sales for the Americas ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... 2020 , ... MedShift , a leading medical technology ... obstacles created as a result of COVID-19. As a provider at the forefront ... and medical manufacturers by expanding access to device offerings, technology services, and marketing ...
(Date:6/28/2020)... HILL, Conn. (PRWEB) , ... June 25, 2020 ... ... company formed to advance photodynamic therapy for treating cancer, today announced the company ... New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals ... be presented June 22-24 during the American Association for Cancer Research Virtual meeting. ... profiles the potent, consistent single agent activity in KEAP1 mutant tumor models of ...
(Date:6/11/2020)... (PRWEB) , ... June 09, 2020 , ... ... the release of the NEON Micro-Tracer Solution, a highly accurate, contact ... COVID-19 virus in the workplace. Contact tracing, a core disease control measure, is ...
Breaking Biology Technology:
Cached News: